Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 83.68

+0.1%

Nov 28 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2884)	6/4/2010 2:44:07 PM
From: Jibacoa	1 Recommendation Read Replies (3) of 3722

Re: ALIM possible competitors. <g> While checking the suggestions offered by some of the Ophthalmologists that answered my question about ALIM's Iluvien, I find that Ophthotech is still private, albeit it seems to have potential.<g> ophthotech.com The other company they mentioned,Thrombogenics, is based in Belgium and trades under symbol THRs in Euronext. Its lead product, microplasmin,is in a PIII for the treatment of vitreomacular adhesion.It is also administered by intaocular injection into the vitreus, Focal vitreomacular adhesion is a condition in which the vitreous gel has an abnormally strong adhesion to the retina. These adhesions can cause vessel and retinal distortion and vitreomacular adhesion is thought to play a key role in numerous retinal conditions such as macular hole formation, and also some forms of macular edema. Vitreomacular adhesion is associated with a much poorer prognosis in patients that suffer from diabetic retinopathy and AMD. medicalnewstoday.com The stock is up today 50% bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next